重要提示 一、本公司董事会及董事、高级管理人员保证年度报告内容的真实性、准确性、完整性，不存在虚假 记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 五、董事会决议通过的本报告期利润分配预案或公积金转增股本预案 2025年度利润分配方案： 云赛智联股份有限公司2025 年年度报告 公司代码：600602 公司简称：云赛智联 900901 云赛 B 股 云赛智联股份有限公司 2025 年年度报告 1 / 182 云赛智联股份有限公司2025 年年度报告 公司拟向全体股东以总股本1,367,673,455股为基数，每10股派现金0.43元（含税），共计分配现 金58,809,958.57元（含税），占公司2025年度合并报表归属于上市公司股东净利润的30.36%；扣除此 次分配股利后的未分配利润1,581,665,024.09元结转以后年度。 如在本公告披露之日起至实施权益分派股权登记日期间，公司利润分配股本基数变动，将按照每10 股派现金0.43元（含税）的比例不变确定分配现金总金额，并将另行公告具体调整情况。 该预案已经公司十二届二十四次董事会会议审议通过，尚需提交公司2025年度股东会审议。 截至报 ...

Financial Performance - The company's operating revenue for 2025 was approximately ¥2.80 billion, a decrease of 4.97% compared to ¥2.94 billion in 2024[15]. - The net profit attributable to shareholders for 2025 was approximately ¥431 million, down 4.06% from ¥449 million in 2024[15]. - The net profit after deducting non-recurring gains and losses was approximately ¥402 million, a decline of 6.38% from ¥429 million in 2024[15]. - The net cash flow from operating activities was approximately ¥390 million, a decrease of 10.74% compared to ¥437 million in 2024[15]. - The basic earnings per share for 2025 was ¥0.48, down 5.88% from ¥0.51 in 2024[15]. - The total assets at the end of 2025 were approximately ¥3.66 billion, an increase of 3.71% from ¥3.53 billion at the end of 2024[15]. - The net assets attributable to shareholders at the end of 2025 were approximately ¥2.98 billion, up 6.98% from ¥2.79 billion at the end of 2024[15]. - The weighted average return on equity for 2025 was 14.94%, down from 16.80% in 2024[15]. - The company reported a total investment of ¥2,183,000,000.00 during the reporting period, a decrease of 23.26% compared to ¥2,844,804,333.34 in the same period last year[85]. - The company’s net profit for the fiscal year 2025 is projected to be ¥203,107,115, after deducting 10% for statutory surplus reserves[178]. Market Trends and Industry Insights - The global consumer electronics industry is expected to reach USD 1.29 trillion in sales by 2025, with a growth rate of approximately 4.8%[27]. - The Asia-Pacific region is projected to account for over 48% of the global market share in consumer electronics by 2025, driven by demand from emerging markets[27]. - In 2025, global wearable devices and audio market is projected to reach a shipment volume of 600 million units, with a year-on-year growth of nearly 10%, and China's market shipment volume expected to be 190 million, growing over 18%[31]. - Global TWS earphone shipments are forecasted to be 300 million units, reflecting a year-on-year increase of 3.4%, while open-type earphones are expected to become a new growth engine with shipments exceeding 40 million units, a growth of 69%[31]. - The consumer electronics industry is experiencing significant changes driven by user demand and technological innovation, particularly in AI applications and product form factor innovations[95]. - The Z generation (ages 18-25) accounts for 38% of the consumer electronics market, emphasizing personalized and social attributes in their purchasing decisions[97]. - The middle-aged group (ages 26-45) represents 42% of the market, focusing on practical, scenario-based, and quality-driven products, with a preference for high-end TWS headphones and high-quality HiFi speakers[97]. Research and Development - The company actively invests in R&D for high-fidelity and low-latency wireless audio products, aligning with national policies to support technological innovation[29]. - The company has significantly increased its R&D investment, enhancing product structure and achieving multiple international design awards, showcasing its strong R&D capabilities and industry-leading design level[39]. - Research and development expenses increased by 30% to $150 million, reflecting the company's commitment to innovation[120]. - The company is focusing on integrating new technologies into audio products, such as advanced sensors and AI capabilities, to enhance user experience and functionality[96]. - The company aims to leverage AI technology to expand product boundaries, enhancing features like real-time translation and health monitoring in wearable devices[96]. Product Development and Innovation - The company has launched multiple brands, including "Xemal," "HECATE," and "AIRPULSE," to diversify its product offerings in the audio market[25]. - The company aims to leverage AI technology in its product development, with a focus on enhancing user experience and product functionality[29]. - The company is developing multi-driver and electronic crossover technologies for headphones to achieve optimal audio playback effects, thereby enhancing market competitiveness[70]. - The integration of AI functionalities in audio products is expanding their application boundaries, allowing them to serve as important carriers for AI edge traffic[30]. - The company has launched various AI-related features in its products, including real-time translation and AI meeting transcription, enhancing its product offerings in line with new technology trends[130]. Marketing and Sales Strategy - The company has established a marketing network with over a hundred regional exclusive distributors across all areas of mainland China, leading in sales on major online platforms like JD and Tmall[50]. - The company has seen steady growth in sales on platforms like Douyin and Xiaohongshu, indicating successful online marketing strategies[50]. - The company is optimizing its channel construction by enhancing traditional online channels and increasing investment in content-based social platforms like Douyin and Xiaohongshu to boost sales[108]. - The company plans to enhance its digital marketing strategy, aiming for a 20% increase in online sales by the end of 2026[120]. Corporate Governance and Management - The company has maintained a strong governance structure, ensuring compliance with relevant laws and regulations, and protecting the rights of all shareholders[134]. - The company has established a comprehensive internal control system to ensure compliance and effective management across all operational aspects[182]. - The company has a core management team with many members having over ten years of tenure, ensuring stability and expertise in management[51]. - The company has a diverse board with members holding positions in other organizations, indicating a broad network and influence in the industry[157]. - The company’s governance and operational decisions were made in compliance with relevant laws and regulations[164]. Social Responsibility and Sustainability - The company has actively participated in social responsibility initiatives, donating 850 portable amplifiers to schools in rural areas to enhance educational quality[129]. - The company has cumulatively donated over 9 million yuan to assist impoverished hearing-impaired children since 2007[189]. - The company has implemented a distributed photovoltaic power generation project with an investment of approximately 3,091 kW, which is expected to generate a total of 3,357,024 kWh in 2025, significantly reducing harmful emissions and improving energy efficiency[128]. - The photovoltaic project not only reduces energy consumption but also alleviates local grid pressure during peak electricity usage times[128]. Future Outlook - The company has set a future outlook with a revenue guidance of $1.5 billion for 2026, indicating a projected growth rate of 25%[120]. - New product launches are expected to contribute an additional $200 million in revenue, with a focus on innovative technology solutions[120]. - The company is exploring strategic acquisitions to enhance its product portfolio, with a budget of $300 million allocated for potential mergers and acquisitions[120]. - The company aims to achieve a 40% increase in R&D investment in 2026 to support innovation and product development[123].

河北华密新材科技股份有限公司 Hebei Huami New Material Technology Co.,LTD 官微二维码 年度报告 （如有） 可视化年报 （如有） 1 2025 华密新材 2 台市任泽区人民政府评为"二零二四年 920247 公司年度大事记 2025 年 2 月，公司被邢台市任泽区人民 政府评为"二零二四年度项目建设工作 '优秀项目投资企业'"。 度项目建设工作'优秀项目投资企业'"。 2025 年 3 月，公司成为河北省质量协会 副会长单位。 2025 年 2 月，公司被邢台市任泽区人民 政府评为"2024 年度经济发展工作'突 出贡献企业'"。 度项目建设工作'优秀项目投资企业'"。 2025 年 5 月，公司被青岛科技大学高分 子科学与工程学院评为"2024 年度最佳 合作企业"。 台市任泽区人民政府评为"二零二四年 2025 年度，公司荣获远大阀门"2025 年 度优秀供应商"称号。 2025 年度，公司被山推集团授予"研发 贡献奖"称号。 | 第一节 | 重要提示、目录和释义 4 | | --- | --- | | 第二节 | 公司概况 7 | | 第三节 | 会计数据和财务 ...

东江环保股份有限公司 2025 年年度报告 东江环保股份有限公司 2025 年年度报告 2026 年 3 月 1 东江环保股份有限公司 2025 年年度报告 第一节 重要提示、目录和释义 公司董事会及董事、高级管理人员保证年度报告内容的真实、准确、完 整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责 任。 公司负责人王碧安、主管会计工作负责人邓国颂及会计机构负责人（会计 主管人员）李新鹏声明：保证本年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本报告涉及的未来计划、发展战略等前瞻性描述不构成公司对投资者的实 质承诺，敬请投资者注意风险。 公司面临行业竞争、安全生产等风险，具体内容详见本报告"第三节 管 理层讨论与分析 十一、公司未来发展的展望 （二）可能面对的风险因素和应 对措施"。 2 公司计划不派发现金红利，不送红股，不以公积金转增股本。 | 目录 | | --- | | 第一节 | 重要提示、目录和释义 2 | | --- | --- | | 第二节 | 公司简介和主要财务指标 7 | | 第三节 | 管理层讨论与分析 11 | | 第四节 | 公 ...

Dividend and Profit Distribution - The proposed cash dividend for the 2025 fiscal year is CNY 1.60 per 10 shares, totaling CNY 750,917,392.96 (including tax) based on a share base of 4,693,233,706 shares[8]. - The total cash dividend for 2025, including the interim dividend of CNY 235,728,539.00, amounts to CNY 986,645,931.96, representing 92.84% of the net profit attributable to shareholders of the parent company[8]. - The cash dividend alone accounts for 81.30% of the net profit attributable to shareholders of the parent company for the 2025 fiscal year[8]. Financial Performance - The company's operating revenue for 2025 reached CNY 2,433,972,457.23, representing a 37.76% increase compared to 2024[48]. - Total profit for 2025 was CNY 1,569,346,339.93, an 87.27% increase from the previous year[48]. - Net profit attributable to shareholders for 2025 was CNY 1,213,553,521.29, up 58.84% from 2024[48]. - The net cash flow from operating activities for 2025 was negative CNY 1,038,188,869.27, a significant decline from the previous year[48]. - Total assets at the end of 2025 amounted to CNY 61,970,584,663.43, a 4.91% increase from 2024[48]. - Total liabilities at the end of 2025 were CNY 36,491,788,408.39, reflecting a 6.04% increase compared to the previous year[48]. - The weighted average return on equity for 2025 was 4.88%, an increase of 1.66 percentage points from 2024[49]. - The liquidity coverage ratio for 2025 was 1,074.77%, significantly higher than the previous year's 698.06%[50]. Company Operations and Structure - The company operates in various financial services, including securities brokerage, self-operated securities, and investment consulting, among others[23]. - Hongta Securities operates 57 brokerage branches, including 2 subsidiaries and 55 securities offices, with 29 located in Yunnan province and 26 in other provinces[37][38]. - The company has a significant presence in major cities, with 3 branches each in Shanghai, Beijing, Chongqing, and Shenzhen[38]. - The company was established in January 2002 with a registered capital of CNY 138,651,040, marking its entry into the securities market[31]. Risk Management - The company emphasizes that its business performance is highly correlated with the domestic macroeconomic environment and capital market trends, which poses significant operational risks[11]. - The company has outlined potential risks in its operations, including market risk, credit risk, liquidity risk, operational risk, and reputational risk[11]. - The company has established a comprehensive risk management system that includes risk culture promotion, risk management policies, and a clear organizational structure for risk management[148]. - The company has implemented a market risk management system with various key risk indicators, including leverage, stop-loss, and sensitivity metrics to manage market risk effectively[152]. Capital and Investment Activities - The company completed its initial public offering of 36.4 million new shares in 2019, raising its registered capital to CNY 3,633,405,396, an increase of approximately 20.5%[32]. - The company has been involved in multiple capital restructuring activities since its inception, enhancing its financial capacity and market presence[31][32][33]. - The company’s proprietary investment business focused on non-directional investments, optimizing investment structures to ensure stable performance growth[78]. - The company increased its investment in bonds related to the "Five Articles of Finance," aligning with central financial work meeting directives[79]. Compliance and Governance - The company has received a standard unqualified audit report from its accounting firm, indicating the financial report's accuracy and completeness[7]. - The company has established a comprehensive internal control system to manage information technology risks effectively[157]. - The company emphasizes the importance of compliance training and monitoring to mitigate legal and compliance risks[158]. - The company has not faced any penalties from securities regulatory authorities in the past three years[192]. Strategic Initiatives and Future Outlook - The company plans to actively engage in market-making services for the Beijing Stock Exchange after obtaining the necessary qualifications[64]. - The company is committed to expanding its market reach and enhancing its service offerings through strategic growth initiatives[39]. - The company plans to enhance its investment banking services and focus on high-quality comprehensive services while managing risks effectively[106]. - The company is committed to enhancing investor returns and market stability through its "Quality Improvement and Return Enhancement Action Plan"[160]. Management and Board Structure - The company completed the reform of the supervisory board on December 5, 2025, eliminating the supervisory board and transferring its functions to the audit committee under the board of directors[169]. - The company appointed new directors including Wang Bin, Liu Xin, and Fan Hua, while several directors including Li Hongshen and Zhang Jing resigned[191]. - The total remuneration for directors and senior management for the fiscal year 2025 amounted to CNY 8.4669 million[189]. - The remuneration structure for senior management includes basic salary, annual performance pay, and deferred payments, with 40% of the annual performance pay being deferred for at least three years[189].

Financial Performance - The company achieved operating revenue of 3.769 billion RMB, representing a year-on-year growth of 4.57%[18] - Net profit attributable to shareholders reached 482 million RMB, an increase of 7.33% year-on-year[18] - The net cash flow from operating activities was 794 million RMB, showing a significant growth of 38.69%[18] - The company's overseas sales revenue reached 329 million yuan in 2025, representing a year-on-year growth of 62.23%[20] - Total operating income for 2025 was approximately 3.77 billion yuan, an increase of 4.57% compared to 2024[30] - The net profit attributable to shareholders for 2025 was approximately 482.30 million yuan, reflecting a growth of 7.33% from the previous year[30] - The net cash flow from operating activities increased by 38.69% year-on-year, amounting to approximately 793.71 million yuan[32] - The company's total assets as of the end of 2025 were approximately 8.61 billion yuan, a 23.15% increase from 2024[30] - The net assets attributable to shareholders reached approximately 7.12 billion yuan at the end of 2025, marking a 27.19% increase compared to the previous year[30] - The basic earnings per share for 2025 was 1.22 yuan, a slight increase of 0.83% from 2024[31] Research and Development - The company invested approximately 144 million RMB in research and development throughout the year[18] - The company aims to build technical barriers for future clinical services through sustained investment in core technologies[18] - The company has accumulated 81 patents and 4 registered certificates by 2025, showcasing its commitment to innovation in the blood purification field[59] - The company has developed a wide range of hemodialyzers, including low-flux, mid-flux, and high-flux series, to meet diverse patient needs[46] - The company has introduced the first neutral peritoneal dialysis solution in China, which is designed to minimize the production of harmful byproducts during storage and heating[51] - The company has developed a wide range of blood dialysis products, including several models of blood dialysis machines and lines, compatible with most dialysis machines on the market[48] - The company has 56 authorized invention patents, 272 utility model patents, and 25 design patents as of December 31, 2025, reflecting its strong R&D capabilities[77] - The company emphasizes a strong research and development system, ensuring efficient product development from design to production[53] Market Strategy and Expansion - The company plans to continue its "dual-wheel drive" strategy focusing on both domestic and international markets[21] - The company is focused on expanding its product line and enhancing its market presence in the blood purification sector[45] - The company has established subsidiaries in various emerging markets, including Ecuador and Indonesia, to enhance local operations[20] - The company is committed to upgrading production automation and refining management to enhance production efficiency and quality control[123] - The company plans to pursue global expansion through technology cooperation, strategic investments, and acquisitions[125] - The company anticipates stable growth in the blood purification industry due to increasing health awareness and aging population in China[119] Governance and Compliance - The company adheres to strict governance practices in compliance with relevant laws and regulations, ensuring transparency and accountability in its operations[134] - The board of directors consists of 9 members, including 3 independent directors with professional backgrounds in management and finance, meeting legal requirements[136] - The company has established a robust information disclosure system to ensure accurate and timely communication with stakeholders, particularly minority shareholders[137] - The company has a structured compensation plan that aligns executive interests with shareholder value through stock grants[141] - The company’s governance structure includes a secretary to the board, ensuring proper documentation and compliance[141] - The company has not faced any penalties from securities regulatory agencies in the past three years[151] - The company’s board committees include an audit committee, nomination committee, compensation and assessment committee, and strategic committee, ensuring comprehensive governance[153] Shareholder Returns and Dividends - The proposed cash dividend distribution is 3.608 RMB per 10 shares, totaling approximately 216.55 million RMB, which accounts for 50.02% of the distributable profits for the year[9] - The company approved a cash dividend of CNY 1.6 per 10 shares for the 2025 interim dividend, totaling CNY 65,821,295.05 (including tax) distributed to shareholders[166] - For the 2025 fiscal year, the company plans to distribute a total cash dividend of CNY 216,546,962.09 (including tax), which represents 44.90% of the net profit attributable to shareholders[168] - The cumulative cash dividend over the last three accounting years amounts to CNY 216,546,962.09, with an average cash dividend ratio of 44.90% of the average annual net profit[170] Industry Trends and Challenges - The number of ESRD patients in China increased from 3.03 million in 2019 to 4.13 million in 2023, with a compound annual growth rate (CAGR) of 8.07%[64] - The blood purification industry in China is projected to grow at a CAGR of 5.67%, reaching a market size of 51.51 billion yuan by 2030[71] - The treatment penetration rate for ESRD patients is expected to rise to 54.29% for hemodialysis and 7.53% for peritoneal dialysis by 2030[74] - The implementation of volume-based procurement policies is expected to accelerate the consolidation of the industry, benefiting larger companies with strong production capabilities[75] - The government has introduced multiple policies to support the development of the blood purification industry, enhancing the market environment for growth[76] - The company faces intensified market competition in the domestic blood dialysis equipment and consumables sector, with a need for continuous technological R&D to maintain competitive advantages[126] Internal Controls and Audit - The internal control system has been effectively implemented, covering all aspects of business activities and internal management[175] - The company’s internal control audit report was issued by Ernst & Young Hua Ming, confirming no significant deficiencies in internal controls[175] - The company has disclosed an internal control audit report with a standard unqualified opinion[176] Leadership and Management - The company has a strong leadership team with extensive experience in finance and management, including positions at Deloitte, KPMG, and Ernst & Young[143] - The current CEO has been with Weigao Blood Purification since 2018, indicating stability in leadership[143] - The leadership structure indicates a commitment to governance and oversight with executives involved in auditing and compliance roles[145][146] - The total remuneration for all directors and senior management at the end of the reporting period amounted to CNY 1,055.28 million[149] Risk Management - The company is at risk of being listed in the medical pricing and procurement dishonesty directory if any dishonest behavior occurs during pricing, bidding, or marketing processes[127] - The company relies on overseas suppliers for key raw materials, and any disruptions in international supply chains could adversely affect production operations[131] - The controlling shareholder will determine any share reduction based on funding needs and investment arrangements after the lock-up period[181]

Dividend Distribution - The company plans to distribute a cash dividend of RMB 0.55 per share (including tax), totaling RMB 533,421,900.55, which represents 33.52% of the net profit attributable to shareholders for the fiscal year 2025[6]. - The total cash dividend for the fiscal year 2025, including share repurchases, amounts to RMB 558,544,686.25, accounting for 35.10% of the net profit attributable to shareholders[7]. - As of February 28, 2026, the total share capital is 972,100,000 shares, with 2,241,999 shares held in the company's repurchase account excluded from the dividend distribution[6]. Financial Performance - The company reported a significant increase in revenue, achieving a total of 1.5 billion RMB, representing a year-over-year growth of 25%[14]. - Total revenue for 2025 reached CNY 45.79 billion, a 1.67% increase from CNY 45.04 billion in 2024[26]. - Net profit attributable to shareholders was CNY 1.59 billion, reflecting a 2.38% increase compared to CNY 1.55 billion in 2024[27]. - Operating cash flow for 2025 was CNY 6.26 billion, down 4.56% from CNY 6.56 billion in 2024[27]. - The gross margin improved to 35%, up from 30% in the previous year, indicating better cost management[14]. - Total profit for 2025 was CNY 1.84 billion, a decrease of 12.71% from CNY 2.11 billion in 2024[27]. Market Expansion and Strategy - The company is expanding its market presence in Southeast Asia, targeting a 10% market share within the next two years[15]. - A strategic acquisition of a local competitor is anticipated to be finalized by Q2 2024, which is expected to increase market penetration[15]. - The company aims to reduce production costs by 15% through operational efficiencies and automation[15]. - The company is focusing on the energy storage market as a second growth engine, with multiple industry benchmark projects underway[64]. Research and Development - The company plans to invest 200 million RMB in research and development for sustainable energy solutions over the next fiscal year[14]. - The company has established a comprehensive research and development system, enhancing its innovation capabilities in the battery industry[71]. - The company has developed a closed-loop air-cooled fuel cell system, addressing lifespan issues and optimizing costs to industry-leading levels[67]. - The company has been involved in various roles within its shareholder units, indicating a strong governance structure[174]. Risk Management - The company has established a comprehensive risk management framework, including a dedicated trading management system to oversee hedging activities[150]. - The company faces risks related to product quality and safety due to complex production processes, which could lead to accidents and negatively impact profitability[105]. - The main raw material, lead, accounts for over 70% of product costs, and significant price fluctuations could adversely affect operating performance due to the linkage between sales prices and raw material costs[103]. Governance and Compliance - The company has implemented significant adjustments to its governance structure, including the cancellation of the supervisory board and the establishment of an audit committee under the board of directors[70]. - The company has made significant governance improvements, including the integration of supervisory functions into the audit committee and the revision of 28 governance-related systems[166]. - The board of directors held 7 meetings during the year, with all meetings conducted via communication methods[187]. Product Development - New product development includes the launch of a next-generation battery technology expected to enhance energy efficiency by 30%[15]. - The company launched a new sodium-ion start-stop battery in August 2025, featuring high safety, long cycle life, and extreme environment resistance[67]. - The company has achieved significant advancements in solid-state battery technology, with prototype products demonstrating energy densities of 300Wh/kg and 400Wh/kg[78]. International Business - The company achieved overseas business revenue of 535 million yuan in 2025, representing a year-on-year growth of 80.54%[69]. - The company is expanding into international markets, particularly in Southeast Asia and Africa, where electric two-wheeler subsidy policies are being implemented[44]. - The company has established deep cooperation with several influential overseas energy storage system integrators and signed framework procurement agreements[69].

Financial Performance - The company reported a net profit attributable to the parent company of -1,225.34 million yuan for the fiscal year 2025, indicating that it has not yet achieved profitability [4]. - The company plans to distribute no cash dividends, stock bonuses, or capital reserve transfers for the fiscal year 2025, pending approval from the shareholders' meeting [7]. - As of the end of the reporting period, the parent company has cumulative unremedied losses of -1,225.34 million yuan, which affects its ability to distribute dividends [8]. - The company reported a significant increase in revenue, achieving a total of 688 million CNY for the fiscal year, representing a growth of 25% year-over-year [17]. - In 2025, the company's operating revenue reached CNY 141.77 million, an increase of 8.83% compared to CNY 130.27 million in 2024 [25]. - The total profit for 2025 was a loss of CNY 245.57 million, an improvement from a loss of CNY 434.51 million in 2024 [25]. - The net profit attributable to shareholders was a loss of CNY 241.61 million, compared to a loss of CNY 440.72 million in the previous year [25]. - The net cash flow from operating activities improved, with a net outflow of CNY 210.18 million, a reduction of CNY 23.70 million from the previous year [27]. - The company's total assets decreased by 16.96% to CNY 705.09 million, while net assets attributable to shareholders fell by 53.18% to CNY 205.54 million [27]. - The weighted average return on equity was -75.34%, reflecting a significant decrease due to the reduction in net asset scale [26]. Research and Development - The company has incurred significant cumulative losses due to ongoing investments in drug research and development, which are characterized by long cycles and high capital requirements [5]. - Research and development expenses amounted to CNY 21.39 million, representing 150.90% of operating revenue, a decrease of 132.02 percentage points from the previous year [26]. - The company is focused on innovative drug development for infectious diseases, aligning with its strategic goals [4]. - The company has initiated 15 clinical research projects for Contezolid tablets, covering various fields including drug-resistant tuberculosis and central nervous system infections [40]. - The company has established a comprehensive R&D system covering all stages of new drug development, from discovery to post-marketing studies [54]. - The company has established two major R&D centers in the US and China, enhancing R&D efficiency and reducing costs [132]. - The company has filed 11 new invention patents during the reporting period, bringing the total to 93 applications and 34 granted patents [135]. - The company is actively expanding its product pipeline with new formulations and production sites for existing drugs [190]. Product Development and Market Strategy - The company has launched its core product, Kangti Zuoan tablets, while multiple other products are in clinical trials both domestically and internationally [4]. - New product development includes the launch of two innovative drug candidates, expected to enter clinical trials in Q3 2024 [17]. - The company is expanding its market presence in Southeast Asia, with plans to enter three new countries by the end of 2024 [17]. - A strategic acquisition of a biotech firm was completed, enhancing the company's R&D capabilities and expected to contribute an additional 50 million CNY in revenue next year [17]. - The company plans to increase its marketing budget by 30% to support the launch of new products and enhance brand visibility [17]. - The company is actively exploring a market expansion strategy combining self-built teams and commercial distribution models [25]. - The company upgraded its commercialization model in 2025, implementing a dual approach of self-built academic promotion teams and third-party academic promotion teams to enhance market coverage [57]. Clinical Trials and Regulatory Approvals - The MRX-4 intravenous formulation has been approved for a Phase III clinical trial in over 20 countries, enrolling 541 patients for the treatment of diabetic foot infections [44]. - The Phase III clinical trial for MRX-4 in treating complex skin and soft tissue infections has been completed, with the NDA application accepted in China [46]. - MRX-8, a new polymyxin antibiotic, has successfully completed its Phase I clinical trial in China, showing proportional drug exposure with increased dosage [47]. - The IND application for MRX-5 in the US was submitted in December 2025 and approved in January 2026, with plans for a Phase IIa study in adults with non-cavitary lung disease [50]. - The company is actively expanding the clinical application of Contizole, initiating a Phase II clinical trial for its use in children aged 6 to 17 for complex skin and soft tissue infections [122]. Market Trends and Competitive Landscape - The company is positioned in the innovative drug sector, focusing on small molecule drug development for infectious diseases, addressing the urgent need for new antibiotics due to rising antimicrobial resistance [66]. - According to WHO, antimicrobial resistance could lead to 10 million deaths annually by 2050 if no action is taken, highlighting the critical need for new drug development [66]. - The market size for antibacterial drugs targeting multi-drug resistant Gram-positive infections in China is projected to reach RMB 5.7 billion by 2025, with a compound annual growth rate (CAGR) of 6.8% from 2020 to 2025 [77]. - The overall market for MDR Gram-positive antibacterial drugs in China is expected to grow at a CAGR of 6.8% from 2020 to 2025, while the oxazolidinone segment is projected to grow at a CAGR of 25.5% from 2025 to 2030 [80]. - The company is focusing on the development of new antibacterial drugs with novel mechanisms to address the increasing resistance of bacteria to traditional antibiotics, indicating a significant market demand [114]. Financial Risks and Challenges - The company is facing risks related to not being profitable, with significant investments in R&D and sales promotion for Kanthizole tablets [143]. - The company is at risk of substantial losses due to high R&D expenditures and reliance on a single product for revenue generation [144]. - The company operates without a controlling shareholder, which may lead to governance instability and decision-making inefficiencies [148]. - The company is exposed to financial risks due to reliance on external financing for operational needs and potential currency fluctuations affecting costs [149].

Financial Performance - The company's operating revenue for 2025 reached RMB 21.63 billion, an increase of 3.19% compared to RMB 20.96 billion in 2024[27]. - The total profit for 2025 was RMB 2.81 billion, reflecting a slight increase of 0.69% from RMB 2.79 billion in 2024[27]. - The net profit attributable to shareholders was RMB 2.17 billion, a marginal increase of 0.34% from RMB 2.16 billion in 2024[27]. - The net cash flow from operating activities surged by 93.46% to RMB 4.48 billion, compared to RMB 2.32 billion in 2024[27]. - The company's total assets as of the end of 2025 amounted to RMB 34.05 billion, a 1.85% increase from RMB 33.43 billion in 2024[27]. - The net assets attributable to shareholders increased by 7.71% to RMB 18.32 billion, up from RMB 17.01 billion in 2024[27]. - Basic earnings per share for 2025 were RMB 0.45, a decrease of 2.17% from RMB 0.46 in 2024[28]. - The weighted average return on net assets was 12.31%, a decrease of 0.16 percentage points from 12.47% in 2024[28]. - The company achieved a revenue of 21.626 billion yuan, representing a year-on-year growth of 3.19%, and a net profit attributable to shareholders of 2.166 billion yuan, with a slight increase of 0.34%[83]. - The total number of stores exceeded 7,300 by the end of the reporting period[83]. Market and Sales Performance - The total revenue for the first quarter was approximately ¥6.19 billion, while the fourth quarter revenue was around ¥6.03 billion, indicating a quarterly fluctuation in sales performance[30]. - The net profit attributable to shareholders for the first quarter was approximately ¥935.20 million, which decreased to ¥303.58 million in the fourth quarter, reflecting a significant decline in profitability[30]. - The online channel generated a revenue of 4.435 billion yuan, accounting for 21.06% of the total revenue during the reporting period[134]. - The company reported a total sales revenue of ¥18.35 billion from chain operations, with a gross margin of 47.00%, an increase of 0.21 percentage points[152]. - The revenue from the South Central region increased by 13.29% to ¥4.71 billion, maintaining a gross margin of 45.44%[152]. - The sales revenue from the top five customers amounted to 1,674.70 million RMB, accounting for 7.74% of the annual total sales[161]. Product and Brand Development - The company continues to develop its own brands, including HLA, OVV, and HLA JEANS, focusing on diverse consumer segments and modern fashion trends[40]. - The partnership with HEAD and the exclusive agency for Adidas FCC products in mainland China are part of the company's strategy to enhance its international brand portfolio[51][53]. - The company has launched the JD Outlet business in collaboration with JD.com, focusing on offering high-quality branded products at lower prices[54]. - The company has established a long-term strategic partnership with Adidas, resulting in the launch of the Adidas FCC series, with 723 authorized Adidas stores by the end of the reporting period[124]. - The brand's new product matrix focuses on high cost-performance, integrating technology, fashion, and quality to meet diverse consumer needs[107]. - The "墨羽轻壳皮肤衣" series was introduced, combining aesthetics and functionality, aimed at becoming a top summer product[110]. Innovation and R&D - Research and development expenses amounted to 212 million RMB, a decrease of 26.42% from the previous year[149]. - The company has a total of 1,280 R&D personnel and holds 460 valid patents, indicating a strong focus on innovation[138]. - The company has introduced innovative products such as anti-wrinkle breathable wool suits and UPF100+ sun protection fabrics, enhancing its product offerings[122]. - The total R&D expenditure for the period was 212.01 million RMB, representing 0.98% of the operating revenue[163]. Supply Chain and Logistics - The company has established a logistics park in Jiangyin, Jiangsu, equipped with advanced logistics and SAP information systems to enhance inventory management and product turnover efficiency[57]. - The company aims to enhance its supply chain management by integrating resources and supporting quality suppliers throughout the production process[59]. - The company has optimized its supply chain management system, enhancing operational efficiency and customer experience[135]. Sustainability and Corporate Responsibility - The company has been recognized as a national-level green factory and a leading brand in the textile and apparel industry, reflecting its commitment to sustainability and innovation[81][82]. - The company is committed to sustainable development, focusing on innovative and environmentally friendly fabric materials[136]. Marketing and Brand Recognition - The company achieved significant brand visibility through its exclusive sponsorship of major events, including the CCTV Spring Festival Gala and the Wuxi Marathon[92]. - Haier Home has been selected as a "Leading Brand" in the "Brand Strong Country Project" for three consecutive years, showcasing its exceptional strength as a national brand[90]. - The company has expanded its marketing network, covering over 80% of counties and cities in China and entering Southeast Asian markets[143]. International Expansion - The company has expanded its international presence, particularly in Southeast Asia, the Middle East, and Africa, adapting to local market needs and climate conditions[78]. - The company has expanded its international presence, opening its first stores in Dubai and Sydney, with a total of 147 overseas stores and a 27.70% year-on-year revenue growth in overseas markets, reaching 450 million yuan in 2025[129][130].

Financial Performance - The company's revenue for 2025 reached RMB 144.145 billion, with a net profit of RMB 15.812 billion, reflecting a resilient business development[4]. - The company's revenue for 2025 reached ¥144.14 billion, an increase of 4.49% compared to ¥137.95 billion in 2024[31]. - Net profit attributable to shareholders decreased by 13.39% to ¥15.49 billion from ¥17.88 billion in the previous year[31]. - The net profit after deducting non-recurring gains and losses was ¥15.99 billion, down 14.71% from ¥18.75 billion in 2024[31]. - The net cash flow from operating activities was ¥30.06 billion, a decline of 19.94% compared to ¥37.54 billion in 2024[31]. - Basic earnings per share decreased by 12.73% to ¥2.88 from ¥3.30 in the previous year[31]. - The net profit for 2025 was CNY 15.812 billion, a decrease of 16.45% compared to the previous year, primarily due to falling pig prices[41]. - The company achieved a revenue of CNY 45.228 billion in the slaughtering and meat business, marking an 86.32% year-on-year growth and achieving profitability for the first time in 2025[41]. Market and Production - In 2025, the company achieved a total of 77.981 million market pigs sold and 28.663 million slaughtered pigs, representing a year-on-year growth of 128.9%[4]. - The company plans to sell 77.981 million commodity pigs in 2025, aligning with its annual operational plan[137]. - For 2026, the company expects to sell between 75 million and 81 million commodity pigs[137]. - In 2025, China's pig production is expected to account for 51% of the global total, maintaining its position as the world's largest pork producer[53]. - The average price of live pigs in 2025 is projected to be 14.44 yuan/kg, a decrease of 9.2% year-on-year, marking the lowest price since 2019[58]. - The number of breeding sows in China decreased by 2.9% year-on-year to 39.61 million by the end of 2025[52]. Sustainability and Environmental Impact - The company reduced greenhouse gas emissions by 6.0588 million tons in 2025, achieving a 2.4% decrease in CO2 equivalent emissions per ton of pork[5]. - The company emphasizes sustainable development and aims to lead the industry in green transformation through shared ammonia reduction and odor control technologies[5]. - The company is committed to sustainable practices, reducing nitrogen emissions through innovative feed formulations[83]. - The company is implementing a full value chain carbon reduction strategy to promote sustainable development and reduce carbon emissions[132]. Technological Innovation - The company invested RMB 6 billion in a super healthy breeding platform to continuously select varieties that meet consumer demands[4]. - The company is committed to smart farming upgrades, including the development of intelligent air filtration pig houses and disease purification systems[5]. - The company has adopted smart farming technologies, including IoT, big data, and AI, to enhance production efficiency and reduce costs[50]. - The company is investing in smart farming technologies to enhance production efficiency and reduce labor costs[129]. - The company has developed a dynamic nutrition model tailored to different pig populations and physiological stages, effectively reducing feed costs[83]. Governance and Management - The company has a clear and independent governance structure, with a board consisting of 8 members, including 3 independent directors[148]. - The company has established a robust investor relations management system, enhancing communication and transparency with investors[150]. - The company maintains independence from its controlling shareholders in assets, personnel, finance, and operations, with no violations reported[151]. - The company has implemented a "Quality and Return Dual Improvement" action plan, although details on its disclosure were not provided[144]. - The company has a structured remuneration management system in place for its directors and senior management[171]. Employee Engagement and Development - The company has created job opportunities for 127,600 people and provided stable new paths for over 7,000 farmers who ceased pig farming[5]. - The company emphasizes talent acquisition and development, fostering a young and international team to drive innovation and growth[91]. - The company has implemented various employee stock ownership plans, involving nearly 5,000 core staff, to enhance employee engagement and drive high-quality development[48]. - The company has developed a comprehensive training system to enhance skills and management capabilities[185]. Financial Management and Control - The company has maintained effective internal financial reporting controls with no significant deficiencies identified during the reporting period[196]. - The company reported zero instances of major defects in financial reporting, indicating strong internal controls[200]. - The total assets of the units included in the internal control evaluation accounted for 100% of the company's consolidated financial statements[198]. - The company has established a comprehensive internal control framework to mitigate risks associated with financial reporting[199]. Strategic Partnerships and Expansion - The company has established strategic partnerships with BAF in Vietnam and Charoen Pokphand Group in Thailand to expand international growth[4]. - The company is actively exploring overseas markets, having established a partnership with BAF in Vietnam and submitted an application for H-share listing in Hong Kong[46]. - The company is strategically expanding into overseas markets with high pork consumption potential, leveraging its advanced breeding technology and management experience[133]. Shareholder Returns - The company plans to distribute cash dividends of approximately RMB 2.435 billion, which accounts for 48.03% of the net profit attributable to shareholders[7]. - The company distributed a total of CNY 8.085 billion in dividends during the reporting period and repurchased shares worth approximately CNY 2 billion[45]. - The company plans to distribute a cash dividend of 5.742689 RMB per 10 shares, totaling 3.083 billion RMB, based on a total share capital of 5,368,356,239 shares after excluding repurchased shares[186].